KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Merck (MRK) Accounts Payables (2016 - 2025)

Merck (MRK) has disclosed Accounts Payables for 17 consecutive years, with $4.4 billion as the latest value for Q4 2025.

  • On a quarterly basis, Accounts Payables rose 7.97% to $4.4 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $4.4 billion, a 7.97% increase, with the full-year FY2025 number at $4.4 billion, up 7.97% from a year prior.
  • Accounts Payables was $4.4 billion for Q4 2025 at Merck, up from $4.1 billion in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $4.6 billion in Q4 2021 to a low of $3.4 billion in Q3 2021.
  • A 5-year average of $3.8 billion and a median of $3.7 billion in 2022 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: fell 10.65% in 2022, then rose 15.64% in 2025.
  • Merck's Accounts Payables stood at $4.6 billion in 2021, then dropped by 7.49% to $4.3 billion in 2022, then fell by 8.02% to $3.9 billion in 2023, then increased by 4.0% to $4.1 billion in 2024, then grew by 7.97% to $4.4 billion in 2025.
  • Per Business Quant, the three most recent readings for MRK's Accounts Payables are $4.4 billion (Q4 2025), $4.1 billion (Q3 2025), and $3.9 billion (Q2 2025).